FDA “Delayering” Initiative Reorganizes Office of Commissioner
This article was originally published in The Gray Sheet
Executive Summary
The Center for Devices & Radiological Health already meets FDA's agency-wide "delayering" goals and will likely be exempted from further restructuring, according to device center staffers
You may also be interested in...
FTE Outsourcing, Further Consolidation Envisioned For FDA By White House
FDA's Office of the Commissioner (OC) will be consolidated further by the end of fiscal 2003 with the assistance of Booz Allen Hamilton consultants
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.